Gene therapy for kidney disease

被引:3
作者
Imai, E [1 ]
Isaka, Y [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Div Nephrol, Osaka, Japan
关键词
gene therapy; HVJ-liposome method; kidney diseases; TGF-beta;
D O I
10.1517/13543784.9.5.1029
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gene therapy has distinct potential to treat disease at the most fundamental level. However, the ability to pursue gene therapy for renal disease has been limited by the availability of an adequate system for gene delivery to the kidney and for regulation of transgene expression. Presently, there are several limitations to overcome before clinical use of viral vector systems for targeting kidney can be considered. Non-viral vectors such as haemagglutinating virus of Japan (HVJ)-liposome mediated gene transfer and cationic liposome are promising but need to be improved. Given that the systemic delivery of the functional protein can serve as therapy for the renal diseases, skeletal muscle targeting gene therapy might be an alternative strategy for the treatment of renal disease. Gene therapy to the transplant kidney may potentially improve the graft outcome by reducing acute and chronic rejection. We review emerging strategies of gene transfer with reference to the kidney and discuss the potential application of gene therapy to renal diseases.
引用
收藏
页码:1029 / 1039
页数:11
相关论文
共 61 条
[1]   Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis [J].
Akagi, Y ;
Isaka, Y ;
Arai, M ;
Kaneko, T ;
Takenaka, M ;
Moriyama, T ;
Kaneda, Y ;
Ando, A ;
Orita, Y ;
Kamada, T ;
Ueda, N ;
Imai, E .
KIDNEY INTERNATIONAL, 1996, 50 (01) :148-155
[2]   In vivo studies with antisense oligonucleotides [J].
Akhtar, S ;
Agrawal, S .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :12-18
[3]  
[Anonymous], USRDS 1998 ANN DAT R
[4]   IN-VIVO TRANSFECTION OF GENES FOR RENIN AND ANGIOTENSINOGEN INTO THE GLOMERULAR CELLS INDUCED PHENOTYPIC CHANGE OF THE MESANGIAL CELLS AND GLOMERULAR SCLEROSIS [J].
ARAI, M ;
WADA, A ;
ISAKA, Y ;
AKAGI, Y ;
SUGIURA, T ;
MIYAZAKI, M ;
MORIYAMA, T ;
KANEDA, Y ;
NARUSE, K ;
NARUSE, M ;
ORITA, Y ;
ANDO, A ;
KAMADA, T ;
UEDA, N ;
IMAI, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 206 (02) :525-532
[5]   Molecular medicine - Antisense oligonucleotide therapy [J].
Askari, FK ;
McDonnell, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :316-318
[6]   Effect of hepatocyte growth factor on chronic rejection in rat renal allografts [J].
Azuma, H ;
Takahara, S ;
Kitamura, M ;
Wang, JD ;
Wega, A ;
Sayegh, MH ;
Suzuki, S ;
Matsumoto, K ;
Nakamura, T ;
Okuyama, A ;
Katsuoka, Y .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :854-855
[7]   Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: Efficient promoter activity of AAV sequences and in vivo delivery via liposomes [J].
Baudard, M ;
Flotte, TR ;
Aran, JM ;
Thierry, AR ;
Pastan, I ;
Pang, MG ;
Kearns, WG ;
Gottesman, MM .
HUMAN GENE THERAPY, 1996, 7 (11) :1309-1322
[8]   Gene silencing as a threat to the success of gene therapy [J].
Bestor, TH .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (04) :409-411
[9]   Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene [J].
Blezinger, P ;
Wang, JJ ;
Gondo, M ;
Quezada, A ;
Mehrens, D ;
French, M ;
Singhal, A ;
Sullivan, S ;
Rolland, A ;
Ralston, R ;
Min, W .
NATURE BIOTECHNOLOGY, 1999, 17 (04) :343-348
[10]  
BORDER WA, 1994, NEW ENGL J MED, V331, P1286